ACE-031 AE1
ActRIIB-Fc fusion protein
Fusion protein of the activin receptor type IIB extracellular domain and human IgG1 Fc, acting as a soluble decoy for myostatin.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- ActRIIB-Fc fusion protein
- Category
- Muscle & Growth Factors
- Type
- Single compound
- Abbreviation
- AE1
- Development and regulatory status
- Not approved; investigational, DMD trial stopped over safety concerns
What researchers study
Fusion protein of the extracellular domain of activin receptor type IIB and human IgG1 Fc. It acts as a soluble decoy that binds myostatin and other negative regulators of muscle growth.
Research areas
- Myostatin-pathway muscle and bone studies
- Lean mass and fat-metabolism biomarkers
- Muscular dystrophy models
- Non-human primate muscle physiology
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- human trial
In 48 healthy postmenopausal women, one dose raised total lean mass by 3.3% and thigh muscle volume by 5.1% at day 29 in the highest-dose group
- phase 2 trial
In ambulatory boys with Duchenne muscular dystrophy, the trial was stopped after the second dosing regimen because of epistaxis and telangiectasias
- non-human primate
In marmosets, 14 weeks of ACE-031 increased lean body mass, muscle fibre area and force production versus vehicle
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Follistatin 344alternative myostatin and activin binder studied in muscle-mass models
- GDF-8myostatin, one of the ligands ACE-031 traps
- IGF-1 LR3IGF-1 pathway studied alongside myostatin blockade
